
Neoadjuvant Atezolizumab Combo Yields High pCR Rates in HER2+ Breast Cancer
Adding atezolizumab (Tecentriq) to trastuzumab (Herceptin) and pertuzumab (Perjeta) followed by epirubicin (Ellence) produced high pathological complete response (pCR) rates among patients with HER2-positive early breast cancer, according to data from the …